Cardioprotective mechanism of telmisartan via PPAR-γ-eNOS pathway in dahl salt-sensitive hypertensive rats

American Journal of Hypertension

Volumn 21, Issue 5, 2008, Pages 576-581

  Kobayashi, Naohiko ^a   Ohno, Tomoyuki ^a   Yoshida, Kohtaro ^a   Fukushima, Hiromichi ^a   Mamada, Yasuko ^a   Nomura, Mika ^a   Hirata, Hisato ^a   MacHida, Yoshifumi ^a   Shinoda, Motoo ^a   Suzuki, Noriko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; COLLAGEN TYPE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN LIGHT CHAIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P22; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RHO KINASE; S6 KINASE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME SYNTHESIS; HEART PROTECTION; HYPERTENSION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; VASCULAR FIBROSIS; VASCULAR LESION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCARDIUM; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR GAMMA; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED DAHL; RESEARCH DESIGN; RHO-ASSOCIATED KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SODIUM CHLORIDE, DIETARY; SUPEROXIDES; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 42549153011     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.27     Document Type: Article

References (24)

1. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994; 91:7355-7359.
2. Sarafidis PA, Lasaridis AN. Actions of peroxisome proliferator-activated receptors-γ agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006; 19:646-653.
3. Sharabi Y, Oron-Herman M, Kamari Y, Avni I, Peleg E, Shabtay Z, Grossman E, Shamiss A. Effect of PPAR-γ agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Am J Hypertens 2007; 20:206-210.
4. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43:993-1002.
5. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.
6. Papademetriou V. The potential role of AT(1)-receptor blockade in the prevention and reversal of atherosclerosis. J Hum Hypertens 2002; 16:S34-S41.
7. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-γ ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 2005; 65:772-781.
8. Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-γ. Int J Biochem Cell Biol 2006; 38:766-781.
9. Cho DH, Choi YJ, Jo SA, Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) γ-dependent and PPARγ-independent signaling pathways. J Biol Chem 2004; 279:2499-2506.
10. Kobayashi N, Mita S, Yoshida K, Honda T, Kobayashi T, Hara K, Nakano S, Tsubokou Y, Matsuoka H, Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 Via NF-κB induced by oxidative stress. Hypertension 2003; 42:1004-1013.
11. Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, Mita S, Nakano S, Tsubokou Y, Matsuoka H. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCε-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 2005; 45:538-544.
12. Ohno T, Kobayashi N, Yoshida K, Fukushima H, Matsuoka H. Cardioprotective effect of benidipine on cardiac performance and remodeling in failing rat hearts. Am J Hypertens 2008; 21:224-230.
13. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, Matsuoka H. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006; 47:671-679.
14. Nascimento NR, Lessa LM, Kerntopf MR, Sousa CM, Alves RS, Queiroz MG, Price J, Heimark DB, Larner J, Du X, Brownlee M, Gow A, Davis C, Fonteles MC. Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide. Proc Natl Acad Sci USA 2006; 103:218-223.
15. Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES, Veves A. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003; 52:173-180.
16. Gonon AT, Bulhak A, Labruto F, Sjoquist PO, Pernow J. Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol 2007; 102:80-89.
17. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor γ-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005; 25:1810-1816.
18. Yano Y, Hoshide S, Ishikawa J, Noguchi C, Tukui D, Takanori H, Tada M, Kanemaru Y, Yano A, Ishikawa S, Shimada K, Kario K. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens 2007; 20:565-572.
19. Mori Y, Itoh Y, Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 2007; 20:431-436.
20. 2 receptors in modulating coronary microvascular function. Circ Res 2003; 92:322-329.
21. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87:840-844.
22. Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, Inoue N, Hirata K, Yokoyama M. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 2006; 186:402-410.
23. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16:3631-3641.
24. Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, Kita T. Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol 2006; 41:989-997.